The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
Antibe Therapeutics is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
Subscribe To Our Newsletter & Stay Updated
